Cite
HARVARD Citation
Bernett, M. et al. (n.d.). 564 Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents. Journal for immunotherapy of cancer. p. A598. [Online].